These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10328990)

  • 41. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.
    Jiang Q; Zheng S; Wang G
    Future Med Chem; 2013 Jun; 5(9):1023-35. PubMed ID: 23734685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.
    Johnston SR; Riddler S; Haynes BP; A'Hern R; Smith IE; Jarman M; Dowsett M
    Br J Cancer; 1997; 75(6):804-9. PubMed ID: 9062399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Tamoxifen in the treatment of breast cancer].
    Charlier C; Colin C; Merville MP; Gielen J; Lambotte R; Plomteux G; Castronovo V
    J Gynecol Obstet Biol Reprod (Paris); 1994; 23(7):751-6. PubMed ID: 7822705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues.
    Pollak M
    Digestion; 1996; 57 Suppl 1():29-33. PubMed ID: 8813463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Strategy of drug development for hormone-dependent tumor].
    Kudoh M
    Gan To Kagaku Ryoho; 1996 May; 23(6):668-72. PubMed ID: 8645015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel antioestrogens without partial agonist activity.
    Wakeling AE; Bowler J
    J Steroid Biochem; 1988 Oct; 31(4B):645-53. PubMed ID: 3199810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.
    Johnson MD; Westley BR; May FE
    Br J Cancer; 1989 May; 59(5):727-38. PubMed ID: 2736207
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.
    Wakeling AE; Valcaccia B; Newboult E; Green LR
    J Steroid Biochem; 1984 Jan; 20(1):111-20. PubMed ID: 6538611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic potential of pure antioestrogens in the treatment of breast cancer.
    Wakeling AE
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):771-5. PubMed ID: 2285589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?
    Gelmann EP
    J Natl Cancer Inst; 1996 Mar; 88(5):224-6. PubMed ID: 8613997
    [No Abstract]   [Full Text] [Related]  

  • 52. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer.
    Jordan VC
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S269-76. PubMed ID: 16402113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New endocrine therapies for breast cancer.
    Howell A; Downey S; Anderson E
    Eur J Cancer; 1996 Apr; 32A(4):576-88. PubMed ID: 8695256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Anti-estrogens and bone tissue].
    Ribot C; Trémollières F
    Ann Endocrinol (Paris); 1995; 56(6):603-8. PubMed ID: 8787352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors.
    Takimoto GS; Graham JD; Jackson TA; Tung L; Powell RL; Horwitz LD; Horwitz KB
    J Steroid Biochem Mol Biol; 1999; 69(1-6):45-50. PubMed ID: 10418980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative mechanisms of action of anti-oestrogens.
    Colletta AA; Benson JR; Baum M
    Breast Cancer Res Treat; 1994; 31(1):5-9. PubMed ID: 7981456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The future of new pure antiestrogens in clinical breast cancer.
    Wakeling AE
    Breast Cancer Res Treat; 1993; 25(1):1-9. PubMed ID: 8518404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives.
    Shagufta ; Ahmad I
    Eur J Med Chem; 2018 Jan; 143():515-531. PubMed ID: 29207335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical uses of antiestrogens.
    Baker VL; Jaffe RB
    Obstet Gynecol Surv; 1996 Jan; 51(1):45-59. PubMed ID: 8657397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pure anti-oestrogens.
    Hermenegildo C; Cano A
    Hum Reprod Update; 2000; 6(3):237-43. PubMed ID: 10874568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.